Related Experiment Video
Updated: Mar 16, 2026
08:18
A Model of Chronic Nutrient Infusion in the Rat
Published on: August 14, 2013
13.2K
Empagliflozin's Fuel Hypothesis: Not so Soon
Gary D Lopaschuk1, Subodh Verma2
1Cardiovascular Translational Science Institute, University of Alberta, Edmonton, AB T6G 2S2, Canada.
Cell Metabolism
|August 11, 2016
Summary
The EMPA-REG OUTCOME trial showed empagliflozin benefits high-risk diabetic patients. However, the exact mechanism, possibly involving ketone oxidation in the heart, requires further investigation.
Area of Science:
- Cardiology
- Endocrinology
- Metabolic Research
Background:
- The EMPA-REG OUTCOME trial demonstrated cardioprotective benefits of empagliflozin in high-risk patients with type 2 diabetes.
- The precise mechanisms underlying these cardioprotective effects remain incompletely understood.
Purpose of the Study:
- To critically evaluate the hypothesis that increased myocardial ketone oxidation mediates the cardioprotective effects of empagliflozin.
- To clarify the role of cardiac ketone metabolism in the context of empagliflozin's benefits.
Main Methods:
- Review and analysis of existing data and literature.
- Assessment of physiological plausibility and supporting evidence for the ketone oxidation hypothesis.
Main Results:
- While empagliflozin's benefits are established, the proposed mechanism of increased myocardial ketone oxidation is not definitively supported.
- Several caveats and limitations challenge the direct causal link between enhanced cardiac ketone utilization and the observed cardioprotection.
Conclusions:
- The contribution of myocardial ketone oxidation to empagliflozin's cardioprotective effects in the EMPA-REG OUTCOME trial is uncertain.
- Further research is necessary to elucidate the complex mechanisms driving empagliflozin's cardiovascular benefits in diabetic populations.
Related Concept Videos
01:24Glucagon-like Receptor Agonists
1.2K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.2K
01:23Dipeptidyl Peptidase 4 Inhibitors
895
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
895
01:18Metabolic States of the Body: The Postabsorptive State
1.5K
The postabsorptive state usually starts about four hours after a meal and lasts until the next meal is eaten. During this time, the digestive system stops absorbing nutrients, and the body uses stored energy reserves to maintain stable blood glucose levels.
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
Initially, glycogen stored in the liver is broken down to release glucose into the bloodstream, while glycogen in the muscles is broken down to supply glucose for energy directly within the muscle cells. As glycogen stores diminish,...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
830
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
830
01:15Hypoglycemia and Glucagon
1.2K
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
1.2K
01:06Oral Hypoglycemic Agents: Glinides
837
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
837